Fabiano Oliveira, M.D., Ph.D.

Section or Unit Name
Vector Molecular Biology Section

Highlight

Exclude from directory
Off
Section/Unit: Location
This Researcher/Clinician’s Person Page
Program Description

Our research focuses on the complex interactions between the human immune system and insect-derived molecules, and how these interactions can influence the outcomes of vector-borne diseases such as dengue, Zika, Chikungunya, and leishmaniasis. When an insect bites, it injects hundreds of arthropod molecules into the host's skin, alerting our immune system to these foreign agents. If the insect is infected with a pathogen, the microorganism is delivered along with these insect-derived molecules. Our immune response to these molecules over time can either help or hinder pathogen establishment, ultimately affecting the disease outcome.

Our work is conducted at two primary locations: the Laboratory of Malaria and Vector Research (LMVR) in Rockville, which is equipped with cutting-edge technologies, and the NIAID International Center of Excellence in Research (ICER) in Cambodia, where we conduct field observations and studies.

At LMVR-Rockville, we use advanced technologies and methodologies to explore the molecular and immunological mechanisms underlying the human response to arthropod bites and the pathogens they transmit. In Cambodia, at the NIAID ICER, we engage in extensive fieldwork to gather critical data and observations directly from affected populations. By integrating field data with laboratory findings, we aim to develop robust hypotheses that can lead to effective strategies for disease mitigation and control.

Our multidisciplinary approach allows us to bridge the gap between laboratory research and field applications. By understanding how the human immune system responds to arthropod molecules, we can identify potential targets for vaccines, therapeutics, and diagnostic tools. Additionally, our research contributes to the development of innovative vector control strategies that can reduce the incidence of these debilitating diseases.

Through collaboration with local communities, healthcare providers, and international partners, we strive to translate our scientific discoveries into practical solutions that can improve public health outcomes. Our ultimate goal is to reduce the burden of vector-borne diseases and enhance the quality of life for people living in endemic regions.

Our research aims to improve dengue prevention and treatment strategies for U.S. travelers, personnel in endemic areas, and regions with reported dengue cases, such as Hawaii, Florida, Texas, Puerto Rico, the U.S. Virgin Islands, and Guam. Enhanced predictive, management, diagnostic, and preventive measures for dengue outbreaks are particularly crucial for these at-risk regions. The development and use of prophylactic therapeutics targeting specific immune responses to mosquito bites could reduce the transmission of arboviruses, including eastern equine encephalitis, Jamestown Canyon, La Crosse, Powassan, St. Louis encephalitis, and West Nile viruses. Improved diagnostic capabilities for vector-borne diseases and emerging infections will lead to better patient outcomes. 

Selected Publications

Manning JE, Chea S, Parker DM, Bohl JA, Lay S, Mateja A, Man S, Nhek S, Ponce A, Sreng S, Kong D, Kimsan S, Meneses C, Fay MP, Suon S, Huy R, Lon C, Leang R, Oliveira F. Development of Inapparent Dengue Associated With Increased Antibody Levels to Aedes aegypti Salivary Proteins: A Longitudinal Dengue Cohort in Cambodia. J Infect Dis. 2022 Oct 17;226(8):1327-1337.

Guerrero D, Vo HTM, Lon C, Bohl JA, Nhik S, Chea S, Man S, Sreng S, Pacheco AR, Ly S, Sath R, Lay S, Missé D, Huy R, Leang R, Kry H, Valenzuela JG, Oliveira F, Cantaert T, Manning JE. Evaluation of cutaneous immune response in a controlled human in vivo model of mosquito bites. Nat Commun. 2022 Nov 17;13(1):7036.

Chea S, Willen L, Nhek S, Ly P, Tang K, Oristian J, Salas-Carrillo R, Ponce A, Leon PCV, Kong D, Ly S, Sath R, Lon C, Leang R, Huy R, Yek C, Valenzuela JG, Calvo E, Manning JE, Oliveira F. Antibodies to Aedes aegypti D7L salivary proteins as a new serological tool to estimate human exposure to Aedes mosquitoes. Front Immunol. 2024 May 1;15:1368066.

Guimaraes-Costa AB, Shannon JP, Waclawiak I, Oliveira J, Meneses C, de Castro W, Wen X, Brzostowski J, Serafim TD, Andersen JF, Hickman HD, Kamhawi S, Valenzuela JG, Oliveira F. A sand fly salivary protein acts as a neutrophil chemoattractant. Nat Commun. 2021 May 28;12(1):3213.

Oliveira F, Rowton E, Aslan H, Gomes R, Castrovinci PA, Alvarenga PH, Abdeladhim M, Teixeira C, Meneses C, Kleeman LT, Guimarães-Costa AB, Rowland TE, Gilmore D, Doumbia S, Reed SG, Lawyer PG, Andersen JF, Kamhawi S, Valenzuela JG. A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates. Sci Transl Med. 2015 Jun 3;7(290):290ra90.

Manning JE, Oliveira F, Coutinho-Abreu IV, Herbert S, Meneses C, Kamhawi S, Baus HA, Han A, Czajkowski L, Rosas LA, Cervantes-Medina A, Athota R, Reed S, Mateja A, Hunsberger S, James E, Pleguezuelos O, Stoloff G, Valenzuela JG, Memoli MJ. Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial. Lancet. 2020 Jun 27;395(10242):1998-2007.

Visit PubMed for a complete publication listing.

Major Areas of Research
  • Characterization of human immune response to ticks, mosquito, and sand fly saliva in the context of medically significant vector-borne diseases (Lyme disease, Powassan, dengue, malaria, and leishmaniasis)
  • Clinical and field epidemiology of the impact of mosquito saliva immunity on the outcome of dengue, Zika, and other diseases carried by mosquitos
  • Strategies to block vector-borne diseases by targeting the arthropod vector and interruption transmission to the human host

Arthropod vectors, including insects and ticks, can transmit infectious disease pathogens among humans or between animals and humans. Arthropod vectors are responsible for the spread and transmission of malaria, dengue fever, chikungunya, yellow fever, Zika, leishmaniasis, Chagas disease, and Lyme disease. According to the World Health Organization, malaria, which is transmitted by mosquitoes, caused an estimated 627,000 deaths in 2020, most of them children under 5 years of age. Other vector-borne diseases such as Chagas disease, leishmaniasis, and schistosomiasis affect hundreds of millions of people worldwide. The burden of these diseases is highest in tropical and subtropical areas, and they disproportionately affect the poorest populations.

NIAID conducts and supports a comprehensive vector biology research program to advance science and identify approaches that will help control or prevent the transmission of vector-borne pathogens to humans. This includes basic research to better understand the biology of arthropod vectors, how they transmit diseases, and how they find and interact with human hosts. The program also supports translational and clinical research to identify and evaluate products and approaches designed to affect vector populations and/or prevent the transmission of pathogens. This includes the development of traps and repellents, the use of biologicals such as Wolbachia bacteria, and the evaluation of novel candidate vaccines based on mosquito saliva.

In 2024, the U.S. Department of Health and Human Services released the National Public Health Strategy to Prevent and Control Vector-Borne Diseases in People (VBD National Strategy). The strategy identifies and describes federal priorities to detect, prevent, respond to, and control diseases and conditions caused by vectors in the United States. It represents the largest formal federal coordination effort focused on vector-borne disease prevention and control with contributions across 17 federal agencies.

Related Public Health and Government Information

For health-related information visit the Centers for Disease Control and Prevention information on mosquitoes.

a mosquito and a needle
vector bio
Page Summary
Arthropod vectors, including insects and ticks, can transmit infectious disease pathogens among humans or between animals and humans. NIAID conducts and supports a comprehensive vector biology research program to advance science and identify approaches that will help control or prevent the transmission of vector-borne pathogens to humans.
Research Area Type
Disciplines & Approaches

Philip P. Adams, Ph.D.

Contact: philip.adams@nih.gov

Education:

Ph.D., 2017, Biomedical Sciences, University of Central Florida, FL
B.S., 2012, Biology, Summa Cum Laude, West Virginia Wesleyan College, WV

Headshot of Philip P. Adams, Ph.D.

Vector Biology Meetings and Workshops

NIH Awards Establish Pandemic Preparedness Research Network

The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness network—called ReVAMPP—will focus its research efforts on “prototype pathogens,” representative pathogens from virus families known to infect humans, and high-priority pathogens that have the potential to cause deadly diseases. The pandemic preparedness research network will conduct research on high-priority pathogens most likely to threaten human health with the goal of developing effective vaccines and monoclonal antibodies.

Contact

Submit a Media Request

Contact the NIAID News & Science Writing Branch.

301-402-1663
niaidnews@niaid.nih.gov
All Media Contacts

World Mosquito Day 2024—The Metabolic Mysteries of Mosquito Metabolism

NIAID Now |

Mosquitoes are considered one of the most dangerous animals on earth because of their broad distribution and the many pathogens they transmit to humans. Some of the most important human diseases in tropical and temperate regions of the planet are caused by mosquito-borne pathogens. Malaria, dengue, and filariasis, among other mosquito-borne diseases, kill or sicken millions of people worldwide every year.

Mosquito-borne pathogens are transmitted to the vertebrate host, such as a human, when the mosquito bites the host in search of blood. The proteins found in blood are essential for female mosquitoes: without it, they lack the resources to create eggs. Greater knowledge of the biological processes involved in the mosquito life cycle could lead to new or improved strategies to control mosquito populations.     

Dr. Patricia Scaraffia, Associate Professor at the Tulane University School of Public Health and Tropical Medicine, has dedicated her career to understanding the metabolism of the mosquito Aedes aegypti that carries the pathogens responsible for dengue, Zika, chikungunya, and yellow fever to humans. NIAID reached out to Dr. Scaraffia about her team’s research. 

What got you interested in studying mosquito metabolism?

I have studied the metabolism of insects that are vectors of pathogens causing human diseases since I was a graduate student at the Universidad Nacional de Cordoba, in Argentina. My Ph.D. dissertation was focused on the energy metabolism in Triatomine insects, vectors of Trypanosoma cruzi, the etiological agent of Chagas´ disease. After my dissertation, I participated as a speaker in a two-week course for PhD students entitled Biochemistry and molecular biology of insects of importance for public health. During the course, Argentinian professors encouraged me to contact the late Dr. Michael A. Wells, a leader in insect metabolism, and apply for a postdoctoral training in his lab. Soon after, I joined Dr. Wells´s lab at the University of Arizona as a research associate and opened a new line of investigation in his lab. Since then, I have never stopped working on A. aegypti mosquito metabolism. I am passionate and curious about the tremendous complexity of mosquito metabolism. It is a fascinating puzzle to work on. It constantly challenges me and my research team to think outside the box when trying to decipher the unknowns related to mosquito metabolism.

A headshot of a smiling woman with curly hair, standing outside against a brilliant sunset

Dr. Patricia Scaraffia's work focuses on the secrets of mosquito metabolism.

Credit: Dr. Patricia Scaraffia

What are the metabolic challenges faced by mosquitoes after feeding on blood?

Female mosquitoes are a very captivating biological system. It is during blood feeding that female mosquitoes can transmit dangerous, and sometimes lethal, pathogens to humans. Interestingly, the blood that the females take could be twice their body weight, which is impressive. Female mosquitoes have evolved efficient mechanisms to digest blood meals, eliminate excess water, absorb and transport nutrients, synthesize new molecules, metabolize excess nitrogen, remove nitrogen waste, and successfully lay eggs within 72 hours! Despite significant progress in understanding how females overcome these metabolic challenges, we have not yet fully elucidated the intricate metabolic pathways, networks, and signaling cascades, nor the molecular and biochemical bases underlying the multiple regulatory mechanisms that may exist in blood-fed female mosquitoes. 

What are the greatest potential benefits of understanding mosquito metabolism?

Metabolism is a complicated process that involves the entire set of chemical transformations present in an organism. A metabolic challenge faced by mosquitoes is how to break down ammonia that results from digesting a blood meal and is toxic to the mosquito. With NIAID support, we found that in the absence of a functional metabolic cycle to detoxify ammonia, A. aegypti mosquitoes use specific metabolic pathways that were believed to be non-existent in insects. This discovery has opened a new field of study. 

A better understanding of mosquito metabolism and its mechanisms of regulation in A. aegypti and other mosquito species could lead us to the discovery of common and novel metabolic targets and/or metabolic regulators. It would also provide a strong foundation for the development and implementation of more effective biological, chemical and/or genetic strategies to control mosquito populations around the world. 

What are the biggest challenges to studying mosquito metabolism?

We have often observed that genetic silencing or knockdown—a technique to prevent or reduce gene expression—of one or more genes encoding specific proteins involved in mosquito nitrogen metabolism results in a variety of unpredictable phenotypes based on our knowledge of vertebrate nitrogen metabolism. Notably, female mosquitoes get control of the deficiency of certain key proteins by downregulating or upregulating one or multiple metabolic pathways simultaneously and at a very high speed. This highlights the tremendous adaptive capacity of blood-fed mosquitoes to avoid deleterious effects and survive.

We have been collaborating closely with scientists that work at the University of Texas MD Anderson Cancer Center Metabolomics Core Facility, and more recently, with bioanalytical chemists that work in the Microbiome Center’s Metabolomics and Proteomics Mass Spectrometry Laboratory in Texas Children’s Hospital in Houston. Our projects are not turn-key type of projects with quick turn-round times. We have to invest considerable time and effort to successfully develop and/or optimize methods before analyzing mosquito samples. Despite these challenges, our research work keeps motivating us to unlock the metabolic mysteries that female mosquitoes hold.

Your research has focused on Aedes aegypti, the main vector of dengue, Zika, etc.  Why did you choose to study this mosquito species rather than others that are also important vectors of malaria and other diseases?

My research has focused on Aedes aegypti not only because it is a vector of pathogens that pose public health threats, but also because it is genetically one of the best-characterized insect species. The availability of the Aedes aegypti genome is a great resource for a wide range of investigations. In addition, Aedes aegypti is relatively simple to rear and maintain in the lab. In my lab, we are interested in expanding our metabolic studies to other mosquito species by working in collaboration with scientists with expertise in the biology of different vectors.

What important questions remain unanswered about mosquito metabolism?

Many important questions remain unanswered about mosquito metabolism. I’d like to highlight a few of them that may help us enhance our knowledge of the mosquito as a whole organism rather than as a linear sum of its parts. For example, what are the genetic and biochemical mechanisms that drive metabolic fluxes in mosquitoes in response to internal or external alterations? How do key proteins interact with each other, and how are they post-translationally regulated to maintain mosquito metabolism? How are the metabolic networks regulated in noninfected and pathogen-infected mosquitoes? What are the critical regulatory points within the mosquito metabolism and the vector-host-pathogen interface? 

While basic science will continue to be crucial in answering these questions, to successfully fight against mosquitoes, we must work together as part of a multidisciplinary team of scientists to tightly coordinate our efforts and close the gap between basic and applied science. 

Contact Information

Contact the NIAID Media Team.

301-402-1663
niaidnews@niaid.nih.gov

Search NIAID Blog

Study Immune Responses Triggered by Bioactive Components in Arthropod Saliva

Funding News Editions:
See more articles in this edition

Through Notice of Special Interest (NOSI): Immune Responses to Arthropod Feeding on Vertebrate Hosts, you can apply for funding to research immunologic events in vertebrate hosts that occur at the bite site (skin) and systemically during and after feeding by hematophagous and ectoparasitic arthropods, as well as how immunologic events and vector salivary factors impact pathogen transmission and pathogenesis, induction or inhibition of protective immune responses, and allergic responses. 

To accomplish those research ends, you could carry out projects like: 

  • Characterizing events in the vertebrate host that occur during and after blood feeding by hematophagous and ectoparasitic arthropods that influence pathogen transmission and pathogenesis, at the bite site and systemically. 
  • Identifying and analyzing salivary factors (e.g., proteins, RNA, peptides, lipids, nucleosides, small molecules) secreted into vertebrate skin during arthropod feeding and their role in immune modulation. 
  • Determining immunological mechanisms that lead to galactose-α-1,3-galactose (alpha-gal) allergy in the vertebrate host following a tick bite, and identifying tick salivary factors that contribute to alpha-gal syndrome. 
  • Examining factors and mechanisms that lead to allergic skin responses and dermatitis in the vertebrate host triggered by ectoparasitic arthropods. 
  • Determining changes in the immune response and impact on pathogen transmission from targeting specific arthropod salivary factors before, during, and after feeding. 

NIAID hopes to foster and strengthen collaborations between immunologists and vector biologists through this NOSI. We will deem nonresponsive any applications that do not include both a vertebrate host immunological component and studies of vector salivary factors. Likewise, project proposals which focus solely on the pathogen are nonresponsive. 

How to Apply 

Submit your application using a parent notice of funding opportunity (NOFO) and list the NOSI’s notice number, “NOT-AI-24-048,” in the Agency Routing Identifier field box (box 4B) of the SF 424 R&R Form. The relevant NOFOs are: 

The limits for your application’s budget request and project period are determined by the NOFO through which you choose to apply. 

So too are the NOSI’s due dates, the earliest of which are October 5, 2024, for R01 applications and October 16, 2024, for R21 applications. The NOSI will remain open until July 16, 2027. 

Direct questions about this initiative to Dr. Qian “Joy” Liu at liujoy@niaid.nih.gov or 301-761-6621 and Dr. Adriana Costero Saint-Denis at acostero@niaid.nih.gov or 301-496-2544.

Contact Us

Email us at deaweb@niaid.nih.gov for help navigating NIAID’s grant and contract policies and procedures.

Stella Self to Develop New Ways to Monitor Spread of Vector-Borne Diseases

Tick Bites and Alpha-Gal Syndrome Focus of $3.5M Research Grant

NIH Awards $3.8M Grant to Advance Development of Tularemia Vaccine